Stockreport

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offer [Read more]